acb stock quote and Investment Insights on Aurora Cannabis

Aurora Cannabis, a major player in the cannabis industry, has been making headlines with its stock performance. ACB stock has been experiencing a rollercoaster ride, with significant fluctuations in its value.

The company's stock has been affected by various factors, including changes in global cannabis regulations and market demand. Aurora Cannabis has been expanding its global presence, which has helped boost its stock value.

Investors are eager to know if ACB stock is a good investment opportunity. To make an informed decision, it's essential to understand the company's financials and growth prospects.

The stock performance of acb stock quote has been a mixed bag over the past year.

In the past day, the stock has seen a slight increase of +0.81%. This is a good sign, but let's not get too excited just yet.

Looking at the bigger picture, the stock has seen significant declines over the past few months. For instance, the current month has seen a drop of -11.76%.

Here's a breakdown of the stock's performance over different time frames:

It's worth noting that the stock has seen some significant declines over the past few years, with a 3-year drop of -90.11% and a 5-year drop of -98.35%.

The financial data for ACB stock is quite impressive. The company's market capitalization is over $10 billion, a significant increase from its initial public offering in 2018.

ACB's revenue has been steadily growing, with a 50% increase in 2020 compared to the previous year. This growth is largely attributed to the company's expansion into new markets and its increasing presence in the cannabis industry.

The company's financial reports also show a significant decrease in its net loss, from $100 million in 2019 to $20 million in 2020. This improvement in financial health is a positive sign for investors.

The Latest Transactions section of the financial data provides a snapshot of recent market activity.

The latest transaction occurred at 04:00:00 pm, with a price of 3.750.

The volume of this transaction was 13,417.

The daily volume is a cumulative total of all transactions, which currently stands at 406,396.

At 03:59:59 pm, the price dropped to 3.740, with a volume of 100.

The daily volume at this time was 392,979.

A pattern of price fluctuations is evident in the data, with prices ranging from 3.740 to 3.750.

The volume of transactions also varies, with some transactions having a volume of 100 and others having a volume of 13,417.

Here is a summary of the latest transactions:

Estimates in CAD are a crucial aspect of financial data. The average revenue estimate for Aurora Cannabis in 2025 is $344 CAD, according to 7 analysts.

As we can see from the data, the average revenue estimate for 2026 is $390 CAD, based on 7 analysts' predictions. This represents a significant increase from the previous year's estimate of $270 CAD.

The number of analysts providing revenue estimates for 2025 is 7, with an average estimate of $344 CAD. In contrast, the number of analysts providing revenue estimates for 2026 is 7, with an average estimate of $390 CAD.

Aurora Cannabis' average earnings estimate for 2025 is 0.604 CAD, based on 6 analysts' predictions. This is a significant improvement from the previous year's estimate of -1.573 CAD.

The average earnings estimate for 2026 is 0.401 CAD, based on 7 analysts' predictions. This represents a decrease from the previous year's estimate of 0.604 CAD.

Here's a summary of the average revenue and earnings estimates for Aurora Cannabis:

These estimates give us a glimpse into the potential financial performance of Aurora Cannabis in the coming years.

Financial Strength is a crucial aspect of a company's overall health.

ACB has a Quick Ratio of 1.15, which indicates that it has sufficient liquid assets to cover its short-term liabilities.

A company's Current Ratio is another important metric, and ACB's ratio of 3.83 shows that it has a strong ability to pay its short-term debts.

AYR.A's Quick Ratio of 0.53 is lower than ACB's, suggesting that it may struggle to cover its short-term liabilities.

WEED's Quick Ratio of 0.97 is also lower than ACB's, indicating that it may have some liquidity issues.

Here's a comparison of the companies' financial strength metrics:

The Interest Coverage metric shows how well a company can pay its interest expenses, and ACB's negative ratio of -4.12 indicates that it may struggle to meet its interest obligations.

AYR.A's Interest Coverage of -1.61 is also negative, suggesting that it may face some difficulties in paying its interest expenses.

WEED's Interest Coverage of -5.70 is the lowest among the three companies, indicating that it may have significant liquidity issues.

The ACB stock quote has been on a rollercoaster ride, with a significant increase in its value over the past year.

This surge can be attributed to the growing demand for cannabis products, particularly in the US market.

The company's revenue has been steadily increasing, with a 50% growth in the last quarter alone.

This growth is expected to continue, driven by the expansion of the company's product portfolio and its strategic partnerships.

Investors are taking notice, with a significant increase in short interest in the stock, indicating a potential buying opportunity.

Let's take a closer look at how Aurora Cannabis has performed compared to the S&P.

Aurora Cannabis has had a tough year, with its stock price down 6.79% over the past 12 months.

The company's five-year performance is even more concerning, with its stock price plummeting 98.39% since 2018.

In fact, the five-year annualized return for Aurora Cannabis is a staggering -56.23%.

Meanwhile, the S&P has seen a much more positive trend, with its stock price up 22.93% over the past year.

Here's a comparison of the two companies' performance over different time periods:

It's clear that Aurora Cannabis has struggled to keep up with the broader market, with its stock price underperforming the S&P in almost every time period.

Aurora Cannabis may be in a better position than Canopy Growth right now, making it a potential outperformer in the long run.

Both Aurora Cannabis and Canopy Growth are highly risky investments, but the data suggests that Aurora may have an edge.

Aurora's current position could be a result of its strong growth strategy and ability to adapt to changing market conditions.

As you're considering investing in Aurora Cannabis, it's essential to stay on top of their upcoming events. Their calendar is packed with earnings reports that can impact their stock price.

Aurora Cannabis has four earnings reports scheduled, with the first one being the Q4 2025 Earnings Release on June 19th, 2025, estimated to be around 0.119 CAD.

The Q1 2026 Earnings Release is set for August 7th, 2025, and is estimated to be around 0.176 CAD. This report might provide valuable insights into the company's performance in the first quarter of 2026.

Aurora Cannabis' Q2 2026 Earnings Release is scheduled for November 6th, 2025, and is estimated to be around 0.102 CAD. This report will give investors a glimpse into the company's second-quarter performance.

Their Q3 2026 Earnings Release is set for February 5th, 2026, and is estimated to be around 0.230 CAD. This report might be a turning point for the company's stock price, depending on their performance in the third quarter of 2026.

Here's a summary of Aurora Cannabis' upcoming earnings reports:

When evaluating a company's investment potential, valuation metrics are a crucial aspect to consider. These metrics help determine if a stock is overvalued, undervalued, or fairly priced.

The Price/Earnings (Normalized) ratio is a key indicator of a company's valuation. For instance, ACB has a Price/Earnings (Normalized) ratio of 7.02, which suggests that investors are willing to pay 7 times the company's normalized earnings.

AYR.A, on the other hand, has a significantly lower Price/Earnings (Normalized) ratio of 0.47, indicating that its stock is undervalued compared to its earnings.

Here's a comparison of the Price/Earnings (Normalized) ratios of the three companies:

The Price/Book Value ratio is another important metric to consider. ACB has a Price/Book Value ratio of 0.51, suggesting that its stock price is lower than its book value.

AYR.A has a Price/Book Value ratio of 0.10, which indicates that its stock price is significantly lower than its book value.

WEED has a Price/Book Value ratio of 0.55, which is relatively close to ACB's ratio.

In general, a lower Price/Book Value ratio can indicate undervaluation, while a higher ratio may suggest overvaluation.